News and Insights

Our CMO speaks with Urban Health Today about who should get screened, the role of primary care physicians in identifying at-risk individuals, and more.

Our vice president of pharmacy explores the hard-to-predict impacts of drug price negotiations on consumers, plans and pharmaceutical companies.

Two Evolent experts discuss the benefits of genetic testing in oncology in American Journal of Managed Care.

Evolent takes a multifaceted approach to help providers navigate shortages of cisplatin, carboplatin and other anti-cancer drugs.

Evolent is leveraging our expertise in two key specialties to reduce cardiovascular damage related to cancer drugs.

Evolent addresses a startling difference in what men and women pay for the same drug.

An Evolent program reduces unnecessary radiation treatments for breast cancer without compromising efficacy.

Evolent's Connie Ducaine writes in MarketWatch that patients need to be proactive to ensure their preferences for end of life are respected.

Our evidence-driven, patient-first model helps produce more informed decisions.

Our solutions are coming together under one brand to improve outcomes for people with complex health conditions.

Company's solutions are coming together to improve outcomes for people living with complex health conditions.

Our chief strategy officer speaks with Becker's about the largely untapped potential of value-based specialty care.

Our chief medical officer shares three trends likely to impact oncology drug spend in the near future.